Sight Diagnostics logo — Morphology-Based Digital Blood Diagnostics

Sight Diagnostics

Morphology-Based Digital Blood Diagnostics

Founded 2011 Israel Israel 95 employees Series D Total: $123.80M AI, Computer Vision +3

General Information

Company Name Sight Diagnostics
Founded Year 2011
Location Israel Israel
Founders / Decision Makers
Team member
Employees 95
Industries AI, Computer Vision, Health Care +2
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Sight Diagnostics. To contact Sight Diagnostics, visit sightdx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Sight Diagnostics compare?

A PDF of Sight Diagnostics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Sight Diagnostics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Sight Diagnostics

Sight Diagnostics, with a last investment of $71.00M in a Series D round on 05 August 2020, is a groundbreaking player in the healthcare industry. The company's flagship product, Sight OLO, has redefined diagnostic testing by delivering a Complete Blood Count in a matter of minutes. This morphological-based digital blood diagnostics technology is universal, accessible, and promises rapid and precise health insights. The proprietary AI algorithms analyze 1,000 detailed images with unparalleled precision, allowing for critical health information to be obtained from just two drops of blood. The company has already made great strides with its initial breakthrough in Malaria detection, and has been deployed across 24 countries, conducting close to a million tests and saving countless lives. With its headquarters in Israel and offices in London, New York, and Tel Aviv, Sight Diagnostics has attracted investments from notable firms including OurCrowd, New Alliance Capital, Go Capital, Koch Disruptive Ventures, Longliv Ventures, and Clal Biotechnology Industries. In an industry where time is critical, Sight Diagnostics is leading the way in revolutionizing healthcare with its innovative diagnostic solutions.

Taxonomy: Diagnostic Testing, Digital Health, AI in Healthcare, Blood Diagnostics, Morphology-Based Analysis, Rapid Testing, Precision Medicine, Healthcare Innovation, Healthcare Access, Malaria Detection, Global Health, Medical Imaging, Point-of-Care Testing

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $71.00M 6
OurCrowd, New Alliance Capital +4
05 Aug 2020
Series C $27.80M 4
OurCrowd, New Alliance Capital +2
14 Feb 2019
Series B $16.00M -
01 Sep 2016
Series A $6.00M -
01 Nov 2014
Seed Round $3.00M -
01 Aug 2011

Sight Diagnostics Alternatives & Competitors

View All Alternatives
Sight Diagnostics vs
Truvian
Truvian United States

blood testing anyone. anywhere.

Venture round
108 employees
Biotechnology, Health Care
Sight Diagnostics vs
Haemokinesis
Haemokinesis Australia

When every second counts.

34 employees
Biotechnology, Health Care
Sight Diagnostics vs

Confirmatory precision diagnostics for tuberculosis (MDR/XDR-TB) within 3 h even at resource-limited...

Series A
27 employees
Biotechnology, Health Care

FAQ About Sight Diagnostics

Morphology-Based Digital Blood Diagnostics
Sight Diagnostics was founded in 2011.
Sight Diagnostics is headquartered in Israel.
Sight Diagnostics operates in AI, Computer Vision, Health Care, Medical Devices and Machine Learning. Its work centres on Diagnostic Testing, Digital Health, AI in Healthcare and Blood Diagnostics.
Sight Diagnostics has approximately 95 employees.
Sight Diagnostics has completed 5 funding rounds, raising a total of $123.80M. The latest funding stage is Series D.
Top alternatives and competitors to Sight Diagnostics include Truvian, Haemokinesis, EMPE Diagnostics, Fyodor Biotechnologies, Astek Diagnostics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Sight Diagnostics and Truvian are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Sight Diagnostics, https://bouncewatch.com/company/sight-diagnostics, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes